Wandercraft Secures $75M to Revolutionize Mobility with Personal Exoskeletons and Humanoid Robots

June 11, 2025
Wandercraft Secures $75M to Revolutionize Mobility with Personal Exoskeletons and Humanoid Robots
  • Wandercraft, a Paris-based robotics company, has recently raised $75 million in a Series D funding round, following a €25 million loan from the EIB and a $45 million Series C round, which has significantly boosted its growth and expansion into the U.S. market.

  • This funding has contributed to a tenfold revenue increase since the last funding round, enhancing Wandercraft's global visibility and product innovation.

  • The new capital will support the commercialization of Eve, the first self-balancing personal exoskeleton, expected to launch in 2026, and will also enhance the Atalante X rehabilitation system and develop the Calvin-40 humanoid robot.

  • Eve is designed for individuals with severe mobility loss, allowing wheelchair users to stand and walk in everyday situations, and is currently undergoing clinical trials to assess its usability.

  • Wandercraft has begun enrolling participants in these clinical trials for its Personal Exoskeleton system, further enhancing its research and development efforts.

  • The Atalante X exoskeleton has already received FDA clearance and is currently in use across over 100 hospitals globally, helping 2,500 individuals with mobility disabilities take over 14 million steps.

  • To further support its mission, Wandercraft has established a center in New York City called 'Walk in New York', offering exoskeleton sessions for individuals with mobility impairments.

  • As the lower-limb exoskeleton market is expected to grow significantly from 2025 to 2030, driven by an aging population, Wandercraft's technology offers a competitive edge in this expanding market.

  • Despite its successes, Wandercraft faces challenges such as scaling production, navigating regulatory approval timelines, and achieving market adoption.

  • The existing Atalante X exoskeleton is priced at €200,000 and has sold 110 units primarily in France, while also gaining traction in the U.S. market.

  • In addition to its rehabilitation technologies, Wandercraft is developing the Calvin line of autonomous humanoid robots, designed to assist workers in physically demanding tasks.

  • Wandercraft's innovations have garnered multiple accolades, including a 2025 Innovation Award at SXSW and recognition in the FT120 Index for leading startups in France.

Summary based on 12 sources


Get a daily email with more Startups stories

More Stories